Reading time: 4 minutes Florence Roan In 2024, the US Food and Drug Administration (FDA) approved lifileucel for the treatment of advanced melanoma. Lifileucel’s approval marked dual milestones. It was the first tumor-infiltrating lymphocyte (TIL) therapy approved for use in cancer, and the first cellular therapy approved for a solid tumor. This new approach—using TILs... Continue Reading →